Thomas Andrew Rowland net worth and biography

Thomas Rowland Biography and Net Worth

Thomas Rowland is ANI’s Senior Vice President, Head of Established Brands. Prior joining ANI in November 2021, Mr. Rowland was the President and Chief Operating Officer of Arbor Pharmaceuticals, a specialty pharmaceuticals company with a portfolio across multiple therapeutic areas. Prior to that, Mr. Rowland was Chief Business Officer at Ventrus Biosciences, a development stage company focused in gastroenterology. Mr. Rowland has more than 30 years of experience in pharmaceutical operations, including in leading commercial organizations as large as 650 personnel and with revenue up to $500 million. Mr. Rowland has also led development team, regulatory, quality and manufacturing functions. Mr. Rowland holds a B.S. in Finance from Metropolitan State University.

What is Thomas Andrew Rowland's net worth?: The estimated net worth of Thomas Andrew Rowland is at least $2.88 million as of May 12th, 2026. Rowland owns 38,271 shares of ANI Pharmaceuticals stock worth more than $2,879,127 as of June 3rd. This net worth evaluation does not reflect any other assets that Rowland may own. Learn More about Thomas Andrew Rowland's net worth.
How do I contact Thomas Andrew Rowland?: The corporate mailing address for Rowland and other ANI Pharmaceuticals executives is 210 Main Street West, Baudette MN, 56623. ANI Pharmaceuticals can also be reached via phone at (218) 634-3500 and via email at [email protected]. Learn More on Thomas Andrew Rowland's contact information.
Has Thomas Andrew Rowland been buying or selling shares of ANI Pharmaceuticals?: During the past quarter, Thomas Andrew Rowland has sold $36,357.39 in ANI Pharmaceuticals stock. Most recently, Thomas Andrew Rowland sold 459 shares of the business's stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $79.21, for a transaction totalling $36,357.39. Following the completion of the sale, the senior vice president now directly owns 38,271 shares of the company's stock, valued at $3,031,445.91. Learn More on Thomas Andrew Rowland's trading history.
Who are ANI Pharmaceuticals' active insiders?: ANI Pharmaceuticals' insider roster includes Stephen Carey (CFO), Stephen Carey (Senior Vice President, Finance and Chief Financial Officer), Meredith Cook (Senior Vice President, General Counsel and Corporate Secretary), Krista Davis (Senior Vice President and Chief Human Resources Officer), Chad Gassert (Senior Vice President, Corporate Development and Strategy), Ori Gutwerg (Senior Vice President, Generics), Thomas Haughey (Director), Nikhil Lalwani (Pres), Nikhil Lalwani (President and Chief Executive Officer), Matthew Leonard (Director), James Marken (Senior Vice President, Operations and Product Development), Christopher Mutz (Insider), Antonio Pera (Director), Thomas Rowland (SVP), Muthusamy Shanmugam (Head of R&D and COO of NJ Operations), Muthusamy Shanmugam (Head of R&D and COO), Renee Tannenbaum (Director), Jeanne Thoma (Director), and Patrick Walsh (Director). Learn More on ANI Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ANI Pharmaceuticals?: During the last year, insiders at the specialty pharmaceutical company sold shares 47 times. They sold a total of 543,295 shares worth more than $46,809,802.49. The most recent insider tranaction occured on May, 13th when VP Meredith Cook sold 500 shares worth more than $39,080.00. Insiders at ANI Pharmaceuticals own 8.1% of the company. Learn More about insider trades at ANI Pharmaceuticals.
Information on this page was last updated on 5/13/2026.

Thomas Andrew Rowland Insider Trading History at ANI Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/12/2026	Sell	459	$79.21	$36,357.39	38,271
3/11/2026	Sell	4,772	$74.91	$357,470.52	38,730
8/12/2025	Sell	4,975	$85.71	$426,407.25	40,794

Thomas Andrew Rowland Buying and Selling Activity at ANI Pharmaceuticals

ANI Pharmaceuticals Company Overview

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Today's Range

Now: $75.23

$73.54

$75.85

50 Day Range

MA: $78.80

$72.82

$84.63

2 Week Range

Now: $75.23

$59.61

$99.50

Volume

257,453 shs

Average Volume

401,969 shs

Market Capitalization

$1.71 billion

P/E Ratio

19.05

Dividend Yield

N/A

Beta

0.44